Annals of Pharmacotherapy最新文献

{"title":"Efficacy of Continuous Infusions of Furosemide-Albumin Compared With Bumetanide in Critically Ill Patients: A Retrospective Cohort Study.","authors":"Sara Hussein, Hala Halawi, Mahmoud Sabawi","doi":"10.1177/10600280261425654","DOIUrl":"10.1177/10600280261425654","url":null,"abstract":"<p><strong>Background: </strong>Continuous loop diuretics are commonly used for management of fluid overload in critically ill patients; however, diuretic resistance remains a challenge. Comparative data on the efficacy of continuous infusions of bumetanide versus furosemide-albumin in patients requiring diuresis are limited.</p><p><strong>Objective: </strong>This study aimed to assess the effects of continuous bumetanide versus continuous albumin-furosemide infusions on urine output in critically ill patients.</p><p><strong>Methods: </strong>This was a retrospective, single health-system cohort study conducted in critically ill adult patients who received continuous bumetanide or continuous albumin-furosemide infusions for at least 24 hours. The primary endpoint was cumulative urine output at 24 hours after diuretic initiation. Secondary endpoints included total diuretic dose, net fluid balance, total albumin administered, changes in serum creatinine, and serum albumin at 24 hours following diuretic initiation, intensive care unit (ICU) length of stay, and in-hospital mortality.</p><p><strong>Results: </strong>Among the 434 patients included, 173 patients received a continuous bumetanide infusion, and 261 patients received a continuous furosemide-albumin infusion. There was no significant difference in urine output at 24 hours between the bumetanide and furosemide-albumin group (3578 mL [1818-4738] vs 3617 mL [2035-4703]; <i>P</i> = 0.304). However, patients in the bumetanide group received a significantly higher total diuretic dose in intravenous furosemide equivalents (481 mg [295-544] vs 177 mg [109-236]; <i>P</i> < 0.001) with no difference in change in serum creatinine (0.08 mg/dL [-0.19 to 0.34] vs 0.10 mg/dL [-0.07 to 0.21]; <i>P</i> = 0.597). Total albumin dose was higher in the furosemide-albumin group (10.9 g [0-12.5] vs 43.7 g [27.5-58.9]; <i>P</i> < 0.001).</p><p><strong>Conclusion and relevance: </strong>This is the first study to evaluate continuous infusions of bumetanide versus furosemide-albumin in critically ill patients requiring diuresis, observing a comparable urine output between diuretics. Findings indicate that bumetanide may be a reasonable alternative in fluid management.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1189-1195"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Oral Cephalosporin and Penicillin Step-Down Therapy for the Treatment of Gram-Negative Blood Stream Infections: A Retrospective Observational Study.","authors":"Bethany Volkmar, Caitlin C Akerman, Alison I Orvin","doi":"10.1177/10600280261426346","DOIUrl":"10.1177/10600280261426346","url":null,"abstract":"<p><strong>Background: </strong>Oral step-down therapy for the treatment of gram-negative blood stream infections (GNBSIs) has been shown to be noninferior to full courses of intravenous (IV) therapy. Studies comparing oral fluoroquinolones, sulfamethoxazole-trimethoprim (SMX-TMP), and beta-lactams have reported similar treatment outcomes, but beta-lactam groups have been small, and efficacy has been questioned given lower oral bioavailability.</p><p><strong>Objective: </strong>This study aims to evaluate the safety and efficacy of oral cephalosporins compared with penicillins for step-down therapy for the treatment of GNBSI.</p><p><strong>Methods: </strong>This was a retrospective study in adult patients admitted for Enterobacterales GNBSI that were transitioned from IV antibiotics to an oral beta-lactam. The primary outcome was treatment failure. Secondary outcomes included components of the primary outcome, microbiological failure, antibiotic-associated adverse drug events (ADEs), and <i>Clostridioides difficile</i> infection (CDI).</p><p><strong>Results: </strong>Overall, 280 patients with GNBSI with step-down to an oral penicillin (<i>n</i> = 140) or cephalosporin (<i>n</i> = 140) were included. More patients in the cephalosporin group had a urinary source of infection (87.9% vs 62.1%, <i>P</i> < 0.001) and urinary abnormalities (40% vs 28.6%, <i>P</i> = 0.044). Treatment failure with oral cephalosporins was noninferior to penicillins (7.1% vs 7.1%; 95% confidence interval [-6.4, 6.4], <i>P</i> = 0.002). No significant differences were found for microbiological failure, antibiotic-associated ADEs, or CDI.</p><p><strong>Conclusion and relevance: </strong>Oral cephalosporins were noninferior to oral penicillins as step-down therapy for Enterobacterales GNBSI. This represents the first comparison of oral beta-lactams for the treatment of GNBSI.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1174-1181"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Plasma Olanzapine Concentrations Associated With Pneumonia.","authors":"Botao Ma, Xufang Sang, Siyuan Qi, Huimei An, Fude Yang","doi":"10.1177/10600280261452550","DOIUrl":"10.1177/10600280261452550","url":null,"abstract":"","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1227-1228"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nerandomilast for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Clinical Efficacy, Safety, and Place in Therapy.","authors":"Phuoc Tyler Bui, Erin St Onge, Hanna Sotolongo-Miranda, Tala Trabulsi","doi":"10.1177/10600280261447319","DOIUrl":"10.1177/10600280261447319","url":null,"abstract":"<p><strong>Objective: </strong>To describe nerandomilast, a preferential phosphodiesterase 4B inhibitor indicated for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.</p><p><strong>Data sources: </strong>A PubMed search was conducted from origin to mid-April 2026 using the terms nerandomilast, Jascyd, BI 1015550, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis, and interstitial lung disease. Phase 2 and 3 clinical trials, prescribing information, pooled analyses, and relevant guideline documents were included.</p><p><strong>Study selection and data extraction: </strong>Two phase 3 randomized controlled trials evaluating nerandomilast in IPF and progressive pulmonary fibrosis were reviewed, along with regulatory prescribing information.</p><p><strong>Data synthesis: </strong>In the FIBRONEER-ILD and FIBRONEER-IPF trials, nerandomilast reduced forced vital capacity decline at 52 weeks compared with placebo. Treatment effects were observed in patients receiving background antifibrotic therapy and those treated with nerandomilast alone. Secondary time-to-event outcomes were not statistically significant. Diarrhea was the most common adverse event and occurred more frequently with nerandomilast, while serious adverse events were similar across treatment groups.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Nerandomilast targets inflammatory and profibrotic pathways distinct from currently available antifibrotic therapies and may be used as monotherapy or in combination with existing agents. Its role is best understood as disease stabilization rather than reversal of established fibrosis.</p><p><strong>Conclusion and relevance: </strong>Nerandomilast represents an additional therapeutic option for patients with IPF and progressive pulmonary fibrosis. Ongoing long-term and real-world data will further clarify its place in clinical practice.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1220-1226"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zoliflodacin for Urogenital Gonorrhea Infections.","authors":"Joshua T Wollen, Abdulwhab Shremo Msdi, Taryn Eubank","doi":"10.1177/10600280261447497","DOIUrl":"10.1177/10600280261447497","url":null,"abstract":"<p><strong>Objective: </strong>To review the pharmacology, efficacy, and safety of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea due to <i>Neisseria gonorrhoeae</i> in adults and pediatric patients 12 years of age and older.</p><p><strong>Data sources and extraction: </strong>A literature search was conducted in Scopus, Web of Science, PubMed Central, Gale Academic FileOne, MEDLINE, Journals@Ovid, and Science Direct databases for all articles relevant to zoliflodacin from inception through February 12, 2026.</p><p><strong>Data synthesis: </strong>Preclinical, pharmacokinetic, and clinical trial data have demonstrated that zoliflodacin is effective against multidrug-resistant (MDR) <i>N. gonorrhoeae</i>, with high urogenital cure rates and no current evidence of increasing minimum inhibitory concentrations. Evidence from phase II and III trials supports its single-dose use as an alternative to ceftriaxone; however, the reduced efficacy for pharyngeal and rectal lesions requires additional evaluation.Relevance to patient care and clinical practice in comparison with existing drugs:Zoliflodacin could serve as an oral alternative to ceftriaxone, particularly for patients with a cephalosporin allergy, and be a viable option for resistance-directed therapy. Continued surveillance will be imperative as zoliflodacin use increases.</p><p><strong>Conclusion: </strong>Zoliflodacin is a novel, first-in-class spiropyrimidinetrione antibiotic for the treatment of uncomplicated urogenital gonorrhea that is efficacious and provides a novel option for MDR <i>N. gonorrhoeae.</i></p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1211-1219"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148040731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.","authors":"Tzu-Rong Peng, Ta-Wei Wu","doi":"10.1177/10600280261454825","DOIUrl":"10.1177/10600280261454825","url":null,"abstract":"","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1229-1231"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of SGLT2 Inhibitors in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Updated Systematic Review and Meta-Analysis.","authors":"Tingyu Wang, Tingfen Wang, Runfeng Zhang","doi":"10.1177/10600280261447498","DOIUrl":"10.1177/10600280261447498","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) constitute a substantial clinical burden with limited therapeutic options. While sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies for heart failure with reduced ejection fraction, their efficacy and safety profile in HFmrEF and HFpEF warrant comprehensive synthesis.</p><p><strong>Objective: </strong>To systematically evaluate the impact of SGLT2 inhibitors on cardiovascular (CV) outcomes, functional capacity, quality of life, and safety in patients with HFmrEF and HFpEF.</p><p><strong>Methods: </strong>Eligible studies compared SGLT2 inhibitors with placebo or standard care in patients with left ventricular ejection fraction (LVEF) > 40%. The primary outcome was defined as CV adverse events, primarily including the composite of first hospitalization for heart failure (HHF) or CV mortality (CV death), first HHF, CV death, all-cause mortality. Secondary outcomes included Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk test distance (6MWTD), and echocardiographic parameters.</p><p><strong>Results: </strong>Eighteen randomized controlled trials comprising 18 774 patients (SGLT2 inhibitors group: 9564; control group: 9210) were included. Meta-analysis showed that SGLT2 inhibitors significantly reduced the risk of the primary composite endpoint (odds ratio [OR]: 0.71; 95% CI: 0.66-0.75, <i>P</i> < 0.00001) and HHF (OR: 0.69; 95% CI 0.64-0.74; <i>P</i> < 0.00001). However, reductions in CV death (HR: 0.92; 95% CI 0.84-1.00; <i>P</i> = 0.05) and all-cause mortality (OR: 0.92; 95% CI 0.84-1.02; <i>P</i> = 0.10) did not reach statistical significance. Subgroup analyses indicated consistent benefits across New York Heart Association classes, body mass index, and concomitant mineralocorticoid receptor antagonists use, with pronounced efficacy observed in patients with renal impairment (estimated glomerular filtration rate ≥60 mL/min/1.73 m²). Furthermore, SGLT2 inhibitors significantly improved KCCQ-total symptom score, 6MWTD, <i>E</i>/<i>e</i>' ratio.</p><p><strong>Conclusion: </strong>SGLT2 inhibitors effectively improve the risk of composite CV death and HHF in patients with HFmrEF and HFpEF, while concurrently improving functional status and quality of life. These findings support the use of SGLT2 inhibitors as a foundational therapy for these populations, although their independent effect on mortality endpoints requires further elucidation.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1196-1210"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148100769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.","authors":"Alejandro Rodríguez Rodríguez, Sandra Caiña López, Tania González Fernández","doi":"10.1177/10600280261456305","DOIUrl":"10.1177/10600280261456305","url":null,"abstract":"","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1232-1233"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Anurag Jha, Nirmal Paudel, Khawaja Arham Jawaid, Muhammad Haad Munir Chaudhry, Zain Ali, Farhan Javaid, Shazia Sharif, Ayesha Asghar, Muhammad Saad, Muhammad Nabeel Saddique","doi":"10.1177/10600280261429462","DOIUrl":"10.1177/10600280261429462","url":null,"abstract":"<p><strong>Background: </strong>Etrasimod is an oral sphingosine-1-phosphate receptor modulator evaluated for induction and maintenance therapy in moderately to severely active ulcerative colitis (UC). This meta-analysis aimed to assess the efficacy and safety of etrasimod in adults with active UC.</p><p><strong>Objectives: </strong>To assess the efficacy and safety of etrasimod as induction and maintenance therapy in adults with moderately to severely active UC.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing etrasimod with placebo in adults (≥18 years) with moderately to severely active UC was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov through November 2025. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with <i>I</i>² and χ² statistics. Analyses were performed with RevMan 5.4.</p><p><strong>Results: </strong>Four RCTs, including 1239 patients (etrasimod = 826; placebo = 413) were analyzed. At 12 weeks, etrasimod significantly improved clinical remission (RR = 2.92, 95% CI 1.71-4.98; <i>I</i>² = 57%), clinical response (RR = 1.71, 95% CI 1.46-2.02; <i>I</i>² = 19%), endoscopic improvement (RR = 1.72, 95% CI 1.30-2.27; <i>I</i>² = 36%), and mucosal healing (RR = 3.11, 95% CI 1.72-5.62; <i>I</i>² = 54%). Beyond 40 weeks, etrasimod increased clinical remission (RR = 4.28, 95% CI 2.72-6.73; <i>I</i>² = 0%), clinical response (RR = 2.20, 95% CI 1.74-2.78; <i>I</i>² = 0%), endoscopic improvement (RR = 3.51, 95% CI 2.36-5.23; <i>I</i>² = 0%), mucosal healing (RR = 6.93, 95% CI 3.61-13.33; <i>I</i>² = 0%), and steroid-free remission (RR = 4.28, 95% CI 2.72-6.73; <i>I</i>² = 0%). Any treatment-emergent adverse event was slightly higher with etrasimod (RR = 1.15, 95% CI 1.04-1.28; <i>I</i>² = 0%), while serious adverse events (RR = 0.79, 95% CI 0.39-1.61; <i>I</i>² = 38%) and discontinuations due to adverse events (RR = 2.17, 95% CI 0.54-8.67; <i>I</i>² = 50%) did not differ significantly.</p><p><strong>Conclusion and relevance: </strong>Etrasimod is effective in inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC, with an acceptable safety profile.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1156-1173"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147525372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Kidney Function Estimation Methods on Carboplatin Dosing and Clinical Outcomes.","authors":"Omar El Khatib, Sara Zekery-Saad, Emna Abidi, Ahmed Abdelaziz, Osama Abu Tabar, Mohammed Ahmed, Anum Farooq, Wasim S El Nekidy","doi":"10.1177/10600280261430829","DOIUrl":"10.1177/10600280261430829","url":null,"abstract":"<p><strong>Background: </strong>The use of the Calvert formula for carboplatin dosing is well established. However, controversy persists regarding the choice of kidney function estimation equations, with oncology and nephrology guidelines offering differing recommendations.</p><p><strong>Objective: </strong>This study aimed to compare the actual carboplatin doses administered to patients with those estimated using various kidney function equations, and to assess whether these differences could influence clinical outcomes.</p><p><strong>Methods: </strong>This retrospective chart review included adult patients who received at least 1 dose of carboplatin at our institution between May 2015 and March 2024. Carboplatin doses were estimated using the Calvert formula with different kidney function equations and compared with the actual doses administered.</p><p><strong>Results: </strong>A total of 360 patients met the inclusion criteria, with a median age of 57 years (46-68), a median weight of 72 kg (61-84), and 248 (68.9%) were female. Significant inter-method variability was observed in the median estimated kidney function and corresponding median carboplatin dosing across equations. Cockcroft-Gault (C-G) using actual body weight (110 mL/min, 677 mg), C-G with adjusted body weight (94 mL/min, 602 mg), 2021 CKD-EPI (chronic kidney disease epidemiology collaboration) (100 mL/min/1.73 m², 649 mg), 2021 CKD-EPI_BSAAdj (101 mL/min, 658 mg), and the Janowitz equation (83 mL/min, 577 mg), <i>P</i> < 0.001. Hematologic toxicity, including febrile neutropenia, was significantly more common in patients dosed using C-G equation with actual body weight compared with adjusted body weight, occurring in 14/20 (70%) versus 5/115 (4.3%), respectively (<i>P</i> < 0.001).</p><p><strong>Conclusion and relevance: </strong>Carboplatin dosing varies significantly depending on the kidney function estimation method used. There is an urgent need for standardized, interdisciplinary dosing guidelines.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1147-1155"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}